[Skip to Navigation]
November 30, 2020

Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease

Author Affiliations
  • 1Knight Alzheimer’s Disease Research Center, Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri
JAMA Neurol. 2021;78(2):141-142. doi:10.1001/jamaneurol.2020.4478
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Aducanumab approval and quality of life
    Ronald Louie, MD | University of Washington
    The authors are right to point out the various impacts of FDA approval for a disease-modifying therapy, especially for dementia, where the pent-up demand and the outcome measures are complicated.

    Since the pertinent FDA advisory committee voting was reportedly negative for aducanumab as it examined the data, one can assume that even if approved, this agent may not have tremendous impact.

    Dr. Jason Karlawish had written a "thought experiment" last year as an "First Opinion" piece in STATnews that delves into practical logistics and financial implications of an approval.

    FDA does approve many cancer agents with marginal
    data and marginal impact; one recent article (cited below) in this journal found that aggregating 92 agents approved recently, median survival increased only two months. Quality of life was not reported; it is hard to determine the value of two months of prolonged survival. Likewise, in dementia care, quality of life should be a consideration if agents prolong survival.

    Ladanie A, Schmitt AM, Speich B, et al. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. JAMA Netw Open. 2020;3(11):e2024406. doi:10.1001/jamanetworkopen.2020.24406